Acute Kidney Injury
Acute Kidney Injury (AKI), also known as acute renal failure (ARF), is a condition characterized by azotemia that progresses over several hours or days, with or without oliguria. AKI is commonly defined as an abrupt decline in renal function, clinically manifesting as a reversible acute increase in nitrogen waste products measured by blood urea nitrogen (BUN) and serum creatinine levels over the course of hours to weeks. The disease leads to an abrupt loss of kidney function, leading to the retention of waste products, electrolyte disturbances, and volume status changes.
- Total Incident Population of AKI in Hospitalized Patients
- Mortality Adjusted Incident Population of AKI in Hospitalized Patients
- Stage-specific Incident Population of AKI
- Age-specific Incident Population of AKI
Acute Kidney Injury Epidemiological Insights Observed in the 7MM (2021)
The total number of incident cases of Acute Kidney Injury observed in the 7MM was observed to be 6 million in the year 2021
The market size of Acute Kidney Injury in the 7MM was found to be approximately USD 5,200 million in 2021
Acute Kidney Injury Market Strengths
The pipeline of AKI is quite robust with diverse products strengthening the upcoming market.
Acute Kidney Injury Market Opportunities
Several biomarkers such as NGAL, Cystatin-C, etc. are being tried and tested to diagnose AKI. Validation of these new biomarkers could provide additional tools to detect the onset and severity of kidney injury.
- SB-101: Sentien Biotechnologies
- RMC-035 (ROSgard): Guard Therapeutics
- OCE-205: Ocelot Bio
- RBT-1: Renibus Therapeutics
- Ilofotase alfa: AM-Pharma
- bRESCAP: Alloksys Life Sciences
- EA-230: Exponential Biotherapies